AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has been given a consensus recommendation of “Hold” by the sixteen research firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $25.57.
A number of brokerages have recently commented on AMAG. Barclays PLC reissued a “hold” rating and issued a $25.00 price objective on shares of AMAG Pharmaceuticals in a research report on Friday, May 5th. ValuEngine raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. TheStreet downgraded shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a research report on Friday, May 5th. Citigroup Inc. decreased their price objective on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating for the company in a research report on Friday, July 7th. Finally, Jefferies Group LLC set a $40.00 price objective on shares of AMAG Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th.
WARNING: This report was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/08/amag-pharmaceuticals-inc-amag-receives-25-57-consensus-pt-from-analysts.html.
In related news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the sale, the senior vice president now owns 28,336 shares of the company’s stock, valued at approximately $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.80% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. State of Alaska Department of Revenue increased its stake in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in shares of AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 510 shares during the last quarter. Advisors Asset Management Inc. increased its stake in shares of AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock valued at $156,000 after buying an additional 5,005 shares during the last quarter. Mason Street Advisors LLC increased its stake in shares of AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock valued at $181,000 after buying an additional 554 shares during the last quarter. Finally, Sei Investments Co. increased its stake in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares during the last quarter.
AMAG Pharmaceuticals (AMAG) traded down 1.83% during midday trading on Friday, reaching $18.75. 368,194 shares of the company’s stock were exchanged. The company’s market cap is $657.09 million. The firm has a 50-day moving average price of $18.77 and a 200 day moving average price of $21.08. AMAG Pharmaceuticals has a 52 week low of $16.00 and a 52 week high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The company had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. During the same quarter last year, the firm posted $1.45 EPS. The company’s quarterly revenue was up 24.3% on a year-over-year basis. Analysts anticipate that AMAG Pharmaceuticals will post $5.31 EPS for the current year.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
